Following reports of 2 temporally associated severe adverse events following immunisation (AEFI), các Austrian Federal Office for Safety in Health Care (the national regulatory body for medicines) have halted the supply and distribution of a specific batch of COVID-19 AstraZeneca.
It is important to note that data from clinical trials shows no evidence of a casual relationship and this halt is being utilised as a precautionary measure only. An immediate review of international reports of similar AEFI show no signals for concern. Vaccine rollout using alternate batches of COVID-19 AstraZeneca continues and further investigations are ongoing.
To read the official announcement follow the link below: